SMARCA2 and non-small cell lung carcinoma: In contrast to SMARCA4-deficient NSCLC in which SMARCA2 is essential for survival (36), SMARCA4-UT and SCCOHT typically exhibit concurrent silencing of SMARCA2 expression (29, 37).